KEMPENI JOACHIM,JOACHIM KEMPENI,WEISS ROBERTA,ROBERTA WEISS,FISCHKOFF STEVEN A.,STEVEN A. FISCHKOFF
申请号：
PL399548
公开号：
PL217702B1
申请日:
2002.06.05
申请国别(地区):
PL
年份:
2014
代理人:
摘要：
Methods of treating disorders in which TNF± activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ± (hTNF ±) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF± (e.g., K d = 10 -8 M or less), a slow off rate for hTNF± dissociation (e.g., K off = 10 -3 sec -1 or less) and neutralize hTNF± activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
